Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Cancer Moonshot: Report Research Trends Released
Posted on January 18th, 2017 by Christine de Vries - Scheidegger in Pharma R&D
Last year we discussed the new Cancer Moonshot, a White House initiative being headed by out-going Vice-President Joe Biden. Taking a page from America’s successful project to put a man on the moon, the idea is to put our most brilliant minds to the task of ending cancer.
Of course the reality is that stopping the scourge of cancer is even more challenging than sending mankind into outer space, so there is not an expectation of simply finding a cure in the next few years (as wonderful as that would be). Rather, the initiative hopes to help expedite the progress in both prevention and treatment of cancer in different ways, including cutting through any government bureaucracy that might be getting in the way and bringing together leaders in fields ranging from oncology to technology.
As a frequent publisher of cancer research findings, Elsevier has the power to be a helpful ally in this effort, and so immediately stepped forward to be a part of the Cancer Moonshot. Dr. Brad Fenwick, Senior VP of Global Strategic Alliances, particularly felt that Elsevier was in an ideal position to use its excellent research solutions to conduct a data-driven analysis that identifies which cancer research collaborations have been the most successful. This insightful information on the research landscape could then be shared widely to help Cancer Moonshot leaders and others to make more informed decisions on the best research investments for advancing the fight against cancer.
The first iteration of this analysis is a report titled Cancer Research: Current Trends & Future Directions, now available here. As the report reminds us, cancer affects the lives of virtually everyone in some way, whether it’s you or someone you care about who gets it, and it is the leading cause of premature death in the U.S. and in 28 European countries. So then it’s not any wonder that this analysis shows that cancer research represented over 4% of ALL research conducted globally in 2014.
The report goes on to use maps and figures to illustrate the cancer research output, growth, and impact in certain countries, as well as the output and impact of top cancer research institutions like the Mayo Clinic, MD Anderson, and Johns Hopkins. It also provides discussion on some research breakthroughs, shows what the “hot topics” have been in cancer research recently, notes which countries are doing the most research, and lists the most cited publications in cancer research.
But this is only the beginning. Elsevier expects to receive feedback on the report and plans to put out several more topic-specific installments, plus an analytical summary in the future – with a hope of releasing a full report by the end of this year. Elsevier’s Scopus database, the largest database of biomedical and clinical research in the world, was key in gathering the data for the report, and no doubt will be used in creating the upcoming installments.
“When completed, and in combination with other materials, this report on cancer research will offer the research community, the public, policy makers, and research funding organizations information at a new level of assessment on the current state of cancer related research. We hope that this will be used to inform the development of new operational approaches, policies, and funding strategies at the laboratory, institutional, national, and international levels.”
Learn more about Scopus, the power behind the report.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Christine de Vries - Scheidegger
Head of Market Development, Corporate R&D at Elsevier
- Working to Uncover the Mode of Action
- Emerging Oncology Drugs in Pharma R&D Pipeline
- Start-Up Spotlight: StemCiTerra, LLC
- Will 2017 be a Black Swan year?
- An Update from Myelo: Expanding Our Team and Evaluating Data